Lumos Diagnostics has kicked off a key paediatric study in the US for its FebriDx rapid diagnostic test, marking a ...
(MENAFN- GlobeNewsWire - Nasdaq) The EMEA point-of-care diagnostics market presents opportunities through rapid diagnostic innovations, especially in infectious disease detection and cardiovascular ...
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented ...
Stockhead on MSN
ASX Quarterly Health Wrap: Lumos lands US$317m deal as ReNerve and Vitrafy hit key milestones
In partnership with the U.S. Army Institute of Surgical Research (USAISR), Vitrafy began the second phase of its platelet ...
During the COVID-19 pandemic, AI-assisted sequencing pipelines were instrumental in tracking SARS-CoV-2 variants, ...
A medical device manufacturer contacted systems integrator Tessy Automation and its parent company, Tessy Plastics, with a ...
Impact of a diagnostic bronchoscopy service with embedded reflex molecular testing within an oncology centre in patients with lung cancer: The Bronchiomics study. This is an ASCO Meeting Abstract from ...
Learn more about whether Artivion, Inc. or QuidelOrtho Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
The U.S. Food and Drug Administration said on Tuesday it had approved the first COVID-19 self-testing kit for home use that provides results within 30 minutes.
The firm hopes to exploit its first-mover advantage in the OTC space following de novo clearance for an at-home PCR test to detect sexually transmitted infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback